SCHEMBL3535637

SCHEMBL3535637

CN1CCN(Cc2ccc3nc(-c4n[nH]c5ccccc45)[nH]c3c2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 1.00
FLT1 P17948 9/20 1.00
KDR P35968 4/20 0.64
PDGFRB P09619 1/20 0.64
ITK Q08881 2/20 0.57
FGFR3 P22607 3/20 0.56
PDPK1 O15530 3/20 0.56
GSK3B P49841 2/20 0.56
CHEK1 O14757 2/20 0.56
ABL1 P00519 2/20 0.56
CDK2 P24941 2/20 0.56
PLK4 O00444 1/20 0.56
AURKA O14965 1/20 0.56
CHUK O15111 1/20 0.56
JAK2 O60674 1/20 0.56
ROCK2 O75116 1/20 0.56
MAP4K4 O95819 1/20 0.56
PAK4 O96013 1/20 0.56
CHEK2 O96017 1/20 0.56
NTRK1 P04629 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541844 0.87 FGFR1 (0.76) FGFR1FLT1KDRPDGFRBFGFR3
SCHEMBL3534013 0.87 FGFR1 (0.76) FGFR1FLT1KDRPDGFRBFGFR3
SCHEMBL3536150 0.86 FGFR1 (0.75) FGFR1FLT1KDRPDGFRBFGFR3
SCHEMBL3533608 0.85 FGFR1 (0.74) FGFR1FLT1KDRPDGFRBFGFR3
SCHEMBL29009529 0.85 FGFR1 (0.73) FGFR1FLT1KDRPDGFRBFGFR3
SCHEMBL3538487 0.84 FGFR1 (0.72) FGFR1FLT1KDRPDGFRBFGFR3
SCHEMBL3536986 0.84 FGFR1 (0.72) FGFR1FLT1KDRPDGFRBFGFR3
SCHEMBL3537054 0.84 FGFR1 (0.72) FGFR1FLT1KDRPDGFRBITK
SCHEMBL3539316 0.84 FGFR1 (0.72) FGFR1FLT1KDRPDGFRBFGFR3
SCHEMBL3536532 0.83 FGFR1 (0.70) FGFR1FLT1KDRPDGFRBFGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885KDR 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.